Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol: A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg)

Contraception

Volumn 59, Issue 3, 1999, Pages 187-193

  Delconte, Anthony ^a   Loffer, Frank ^b   Grubb, Gary S ^a  

^a WYETH AYERST RESEARCH   (United States)

^b Gynecology   (United States)

Author keywords

Cycle control; Ethinyl estradiol; Intermenstrual bleeding; Levonorgestrel; Norethindrone; Oral contraceptive

Indexed keywords

ALESS; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; LEVONORGESTREL; NORETHISTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVULATION INHIBITION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

CONTRACEPTIVES, ORAL, HORMONAL; ETHINYL ESTRADIOL; FEMALE; HEMORRHAGE; HUMANS; LEVONORGESTREL; MENSTRUAL CYCLE;

EID: 0033001908     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00019-0     Document Type: Article

References (16)

1. Spona J., Feichtinger W., Kindermann C., et al. Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinylestradiol. Contraception. 54:1996;299-304.
2. Archer D.F., Maheux R., DelConte A., O'Brien F.B. A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg. Contraception. 55:1997;139-144.
3. Bannemerschult R., Hanker J.P., Wunsch C., et al. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low-dose oral contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel over six treatment cycles. Contraception. 56:1997;285-290.
4. Belsey E.M., Machin D., d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 34:1986;253-260.
5. Preston S.N. A report of a collaborative dose-response clinical study using decreasing doses of combination oral contraceptives. Contraception. 6:1972;17-35.
6. Wilde M.I., Balfour J.A. Gestodene a review of its pharmacology, efficacy and tolerability in combined contraceptive preparations . Drugs. 50:1995;364-395.
7. Van der Vange N. Ovarian activity during low dose oral contraceptives. Chamberlain G. Contemporary Obstetrics and Gynecology. 1988;315-326 Butterworth, London.
8. Fotherby K. Pharmacokinetics and metabolism of progestins in humans. Goldzieher J.W. Pharmacology of the Contraceptive Steroids. 1994;99-126 Raven Press, New York.
9. Back D.J., Bates M., Breckenridge A.M., et al. The pharmacokinetics of levonorgestrel and ethinyl estradiol in women - studies with Ovral® and Ovranette.® Contraception. 23:1981;229-239.
10. Back D.J., Breckenridge A.M., Crawford F.E., et al. Kinetics of norethindrone in women II. Single-dose kinetics . Clin Pharmacol Ther. 24:1978;448-453.
11. Rosenberg M.J., Long S.C. Oral contraceptives and cycle control a critical review of the literature . Adv Contracept. 8:(suppl 1):1992;35-45.
12. DelConte A., Martin D.J., Gast M.J. A multicenter, randomized, comparative trial of the effects on cycle control of two 21-day oral contraceptive regimens. (abst) Eur J Contracept Reprod Health Care. 3:(suppl1):1998;49.
13. Appel T.B., Kambi A.A., Birdsall C., et al. A comparison of a new graduated estrogen formulation with three-constant-dosed oral contraceptives. Contraceptives. 35:1987;523-532.
14. Rosenberg M.J., Waugh M.S., Meehan T.E. Use and misuse of oral contraceptives risk indicators for poor pill-taking and discontinuation . Contraception. 51:1995;283-288.
15. Rosenberg M.J., Waugh M.S., Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med. 40:1995;355-360.
16. Steroid Contraception and the Risk of Neoplasia. Technical Report Series No. 619. 1978;World Health Organization, Geneva.